Financial Instruments and Fair Value Measurements (Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration) (Details) (Recurring, Contingent Consideration, CNS Therapeutics, Inc., USD $) In Millions, unless otherwise specified	6 Months Ended
	Mar. 28, 2014
Recurring | Contingent Consideration | CNS Therapeutics, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 6.9
Accretion expense	0.1
Ending balance	$ 7.0